December 10, 2025: Supplement – Conference Highlights ESMO 2025   (View All Issues)

Gastroesophageal Cancer

JULIA CIPRIANO, MS, CMPP  / December 10, 2025: Supplement – Conference Highlights ESMO 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...

Lung Cancer

Chase Doyle  / December 10, 2025: Supplement – Conference Highlights ESMO 2025

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...